Cytek Biosciences, Inc.

Cytek Biosciences, Inc.

CTKB·NASDAQ

$4.29

+2.3%
HealthcareMedical - Devices

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

At a Glance

Live Snapshot
Market Cap$553.38M
EPS-0.5200
P/E Ratio-8.24
Earnings Date08/05/2026

ctkb

Total Liabilities and Equity

Last Annual Value

461.54M

3-Year CAGR

-4%

5-Year CAGR

16%

10-Year CAGR

21%

Cytek Biosciences, Inc.

Cytek Biosciences, Inc. Competitors Analysis of Total Liabilities and Equity

CTKB · NASDAQ
CompanyTotal Liabilities and Equity
CAGR 3Y
CAGR 5Y
CAGR 10Y
461.54M
-2.3%-0.1%N/A 
97.75M
31.8%8.3%29.4%
598.73M
9.2%6.2%6.8%
1.07B
-14.1%-7.7%-6.4%
280.14M
-19.3%-13.0%-9.1%
508.63M
5.1%10.5%32.4%
1.11B
-3.9%-0.7%N/A
567.75M
20.7%15.6%6.4%
SRDX logo
Surmodics, Inc.
NASDAQ:SRDX
178.56M
-1.3%-1.7%3.0%
CBLL logo
CeriBell, Inc.
NASDAQ:CBLL
195.80M
49.2%N/AN/A
190.58M
-8.9%6.2%N/A
Cytek Biosciences, Inc.

Cytek Biosciences, Inc. Fair Value Envelope

CTKB · NASDAQ

Our analysis suggests that CTKB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.285, this represents a potential HIDDEN relative to our calculated worth for Cytek Biosciences, Inc..

Intrinsic Value
Current Price: $4.285